Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis — Stella

Home/Multiple Sclerosis/Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

View on ClinicalTrials.gov

Recruiting

Back to Multiple Sclerosis trials

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

United States

Northwestern Memorial Hospital, Chicago, Illinois

Key details

Phase

Post-approval study

Sponsor

Northwestern University

Collaborators

TG Therapeutics, Inc.

Enrollment target

~40 participants

Started

November 2025

Primary completion

March 2029

Age range

18 Years – 70 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.